Applications

1195 – F-18 Flurodeoxyglucose Positron Emission Tomography (FDG PET) for the diagnosis of Alzheimer's Disease

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

-

Service or technology in this application

FDG is a slightly radioactive form of glucose that can be safely injected into a patient. After 30 minutes a scan can then be performed with a PET camera, which takes approximately 15 minutes.

Medical condition this application addresses

Alzheimer’s disease is the most common cause of dementia. It is progressive and leads to severe disability and then morbidity – on average seven years from diagnosis. Symptoms of Alzheimer’s disease are present for several years before diagnosis and the pathological process that leads to the dementia of Alzheimer’s disease begins a decade or more before diagnosis.

Meetings to consider this application

  • PASC meeting: 
    • 16 to 17 April 2014
    • 14 to 15 August 2014
  • ESC meeting:
    • 12 to 13 February 2015
  • MSAC meeting:
    • 1 to 2 April 2015